Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review
Zhimin Chen,1,2 Pengjun Xie,1,2 Qihai Chen,1,2 Jie Ouyang1– 3 1The First Clinical Medical College of Guangdong Medical University, Zhanjiang, People’s Republic of China; 2Department of Breast Surgery, Dongguan Dungwah Hospital, Dongguan, People’s Republic of China; 3Dongguan Key Laboratory of Breast...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-06-01
|
| Series: | Breast Cancer: Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/advancements-in-dalpiciclib-for-the-treatment-of-breast-cancer-patient-peer-reviewed-fulltext-article-BCTT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839645417125445632 |
|---|---|
| author | Chen Z Xie P Chen Q Ouyang J |
| author_facet | Chen Z Xie P Chen Q Ouyang J |
| author_sort | Chen Z |
| collection | DOAJ |
| description | Zhimin Chen,1,2 Pengjun Xie,1,2 Qihai Chen,1,2 Jie Ouyang1– 3 1The First Clinical Medical College of Guangdong Medical University, Zhanjiang, People’s Republic of China; 2Department of Breast Surgery, Dongguan Dungwah Hospital, Dongguan, People’s Republic of China; 3Dongguan Key Laboratory of Breast Cancer Prevention and Treatment, Dongguan, People’s Republic of ChinaCorrespondence: Jie Ouyang, Email kitty865@163.comAbstract: Combining cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6 inhibitors) with cyclin-dependent proteins can reduce the formation of cyclin D-CDK4/6 complexes, resulting in the inactivation of downstream genes and suppression of cell proliferation. Previous research on the use of CDK4/6 inhibitors in combination with endocrine therapies and anti-HER2 targeting agents across various subtypes and stages of breast cancer has shown promising outcomes in patient prognoses and tolerable drugs toxicities. For the present, the CDK4/6 inhibitors that have been widely used for the treatment of breast cancer are palbociclib, abemaciclib and ribociclib. Dalpiciclib (SHR6390), a novel and selective CDK4/6 inhibitor developed in China, has been approved by the National Medical Products Administration. The researches about dalpiciclib with different anti-tumor drugs are ongoing to explore the efficacy and the best strategies to use dalpiciclib. This review provides an overview of the research progress on dalpiciclib across different breast cancer subtypes with various anti-tumor drugs in different treatment opportunities.Keywords: breast cancer, dalpiciclib, CDK4/6 inhibitors, cyclin D |
| format | Article |
| id | doaj-art-a2c752f808b94e5da394f8f2d74ef04e |
| institution | Matheson Library |
| issn | 1179-1314 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Breast Cancer: Targets and Therapy |
| spelling | doaj-art-a2c752f808b94e5da394f8f2d74ef04e2025-07-01T17:36:22ZengDove Medical PressBreast Cancer: Targets and Therapy1179-13142025-06-01Volume 17Issue 1557565104345Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A ReviewChen ZXie P0Chen Q1Ouyang J2Galactophre DepartmentGalactophre DepartmentGlactophore DepartmentZhimin Chen,1,2 Pengjun Xie,1,2 Qihai Chen,1,2 Jie Ouyang1– 3 1The First Clinical Medical College of Guangdong Medical University, Zhanjiang, People’s Republic of China; 2Department of Breast Surgery, Dongguan Dungwah Hospital, Dongguan, People’s Republic of China; 3Dongguan Key Laboratory of Breast Cancer Prevention and Treatment, Dongguan, People’s Republic of ChinaCorrespondence: Jie Ouyang, Email kitty865@163.comAbstract: Combining cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6 inhibitors) with cyclin-dependent proteins can reduce the formation of cyclin D-CDK4/6 complexes, resulting in the inactivation of downstream genes and suppression of cell proliferation. Previous research on the use of CDK4/6 inhibitors in combination with endocrine therapies and anti-HER2 targeting agents across various subtypes and stages of breast cancer has shown promising outcomes in patient prognoses and tolerable drugs toxicities. For the present, the CDK4/6 inhibitors that have been widely used for the treatment of breast cancer are palbociclib, abemaciclib and ribociclib. Dalpiciclib (SHR6390), a novel and selective CDK4/6 inhibitor developed in China, has been approved by the National Medical Products Administration. The researches about dalpiciclib with different anti-tumor drugs are ongoing to explore the efficacy and the best strategies to use dalpiciclib. This review provides an overview of the research progress on dalpiciclib across different breast cancer subtypes with various anti-tumor drugs in different treatment opportunities.Keywords: breast cancer, dalpiciclib, CDK4/6 inhibitors, cyclin Dhttps://www.dovepress.com/advancements-in-dalpiciclib-for-the-treatment-of-breast-cancer-patient-peer-reviewed-fulltext-article-BCTTBreast cancerDalpiciclibCDK4/6 inhibitorsCyclin D |
| spellingShingle | Chen Z Xie P Chen Q Ouyang J Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review Breast Cancer: Targets and Therapy Breast cancer Dalpiciclib CDK4/6 inhibitors Cyclin D |
| title | Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review |
| title_full | Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review |
| title_fullStr | Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review |
| title_full_unstemmed | Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review |
| title_short | Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review |
| title_sort | advancements in dalpiciclib for the treatment of breast cancer patients a review |
| topic | Breast cancer Dalpiciclib CDK4/6 inhibitors Cyclin D |
| url | https://www.dovepress.com/advancements-in-dalpiciclib-for-the-treatment-of-breast-cancer-patient-peer-reviewed-fulltext-article-BCTT |
| work_keys_str_mv | AT chenz advancementsindalpiciclibforthetreatmentofbreastcancerpatientsareview AT xiep advancementsindalpiciclibforthetreatmentofbreastcancerpatientsareview AT chenq advancementsindalpiciclibforthetreatmentofbreastcancerpatientsareview AT ouyangj advancementsindalpiciclibforthetreatmentofbreastcancerpatientsareview |